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Abstract
Background: Investigation of genetic heterogeneity and spoligotype-defined lineages of drug-resistant Mycobacterium
tuberculosis clinical isolates collected during a three-year period in two university hospitals and National Tuberculosis
Reference and Research Laboratory in Ankara, Turkey.
Methods and Findings: A total of 95 drug-resistant M. tuberculosis isolates collected from three different centers were
included in this study. Susceptibility testing of the isolates to four major antituberculous drugs was performed using
proportion method on Lo ¨wenstein–Jensen medium and BACTEC 460-TB system. All clinical isolates were typed by using
spoligotyping and IS6110-restriction fragment length polymorphism (RFLP) methods. Seventy-three of the 95 (76.8%) drug
resistant M. tuberculosis isolates were isoniazid-resistant, 45 (47.4%) were rifampicin-resistant, 32 (33.7%) were streptomycin-
resistant and 31 (32.6%) were ethambutol-resistant. The proportion of multidrug-resistant isolates (MDR) was 42.1%. By
using spoligotyping, 35 distinct patterns were observed; 75 clinical isolates were grouped in 15 clusters (clustering rate of
79%) and 20 isolates displayed unique patterns. Five of these 20 unique patterns corresponded to orphan patterns in the
SITVIT2 database, while 4 shared types containing 8 isolates were newly created. The most prevalent M. tuberculosis lineages
were: Haarlem (23/95, 24.2%), ill-defined T superfamily (22/95, 23.2%), the Turkey family (19/95, 20%; previously designated
as LAM7-TUR), Beijing (6/95, 6.3%), and Latin-America & Mediterranean (LAM, 5/95 or 5.3%), followed by Manu (3/95, 3.2%)
and S (1/95, 1%) lineages. Four of the six Beijing family isolates (66.7%) were MDR. A combination of IS6110-RFLP and
spoligotyping reduced the clustering rate from 79% to 11.5% among the drug resistant isolates.
Conclusions: The results obtained showed that ill-defined T, Haarlem, the Turkey family (previously designated as LAM7-
TUR family with high phylogeographical specifity for Turkey), Beijing and LAM were predominant lineages observed in
almost 80% of the drug-Resistant M. tuberculosis complex clinical isolates in Ankara, Turkey.
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Introduction
Tuberculosis (TB) continues to be one of the prevalent
infectious diseases. The global spread of the disease is further
complicated by the ubiquitous appearance of drug resistant and
especially MDR isolates (the latter being defined by combined
resistance to isoniazid [INH] and rifampicin [RIF]) [1,2]. One of
the greatest concerns of TB control programs is the emergence
and spread of drug resistant and MDR-TB. According to a recent
report of the Ministry of Health [3], with an incidence rate of 30
per 100,000 inhabitants, there were 16.760 new TB cases in
Turkey in 2008 while the total number of TB cases was 18.452.
The available figures for Ankara for the same year reported a total
of 665 TB cases (55.8% male, 44.2% female, sex-ratio 1.26), with
smear and culture positivity rates of 56.2% and 71.4%,
respectively. The resistance proportion to isoniazid, rifampicin,
ethambutol, streptomycin, and MDR were 13.8%, 6.6%, 4.3%,
7.5%, and 5.3% respectively [3]. According to the results of the
previous studies from different parts of Turkey, the resistance rates
to at least one drug ranged from 14.9% to 40.2% [4–7]. Also,
MDR rates were between 1.7% and 19.7% [4–6].
Study of genotyping diversity of drug resistant M. tuberculosis
isolates from infected individuals can provide useful information
about the origin and transmission of the drug resistant isolates [8–
11]. Although the rates of drug resistant M. tuberculosis isolates are
high in Turkey, the information about resistant M. tuberculosis
genotypes circulating in the country is very limited. Despite several
publications dealing with M. tuberculosis genotyping in Turkey
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30331[1,8,12–16], only two investigations reported spoligotyping-based
characterization of drug resistant M. tuberculosis isolates [1,8]. This
study was therefore planned to estimate the clustering rate and
pinpoint precisely the prevalent lineages among the drug resistant
M. tuberculosis isolates in Ankara, the capital city of Turkey. For this
purpose we used spoligotyping and IS6110-RFLP that are two
well-established methods used frequently to highlight transmission
dynamics and phylogenetic distribution of M. tuberculosis isolates all
over the world [10,17–19]. PCR-based spoligotyping is rapid, cost-
effective, and allows concomitantly to differentiate mycobacterial
species within the M. tuberculosis complex as well as to easily
identify specific genotypes such as those belonging to the Beijing
lineage [20], while IS6110-RFLP allows to substantially reduce the
overestimation of clustered M. tuberculosis isolates by spoligotyping
used alone as a first-line typing method [12].
Materials and Methods
Patient population and bacterial isolates
Our analysis was based on 95 M. tuberculosis isolates from various
clinical samples from 2004 to the end of 2006 (1 isolate per patient;
n=35 from Mycobacteriology laboratory of Gulhane Military
Medical Academy, n=33 from Hacettepe University, and n=27
from National TB Reference and Research Laboratory in the
Refik Saydam Hygiene Center, Ankara). The ages of the 95
patients ranged from 19 to 70 years, with a mean of 38.12619.18.
It should be noted that all M. tuberculosis isolate found to be drug-
resistant from the study laboratories over the study period were
included in this study and no other selection criteria than drug-
resistance were retained. More specifically, due to a lack of
systematicsampling in ourregion, it is difficult to interpret ourstudy
sample in terms of representativity in a national context; hence we
have arbitrarily decided to designate it as a ‘‘convenience sample’’.
Identification and drug susceptibility testing
Differentiation of the M. tuberculosis complex and non-tubercu-
lous mycobacteria was achieved by selective inhibition of the M.
tuberculosis isolates in the presence of 5 ml/ml of p-nitro-a-acetyl-
amino-b-hydroxypropiophenone (NAP) according to the BAC-
TEC manual [21]. All isolates grown on LJ media were identified
as M. tuberculosis by using biochemical tests, including production
of niacin, catalase activity, nitrate reduction, pigment production
and growth rate [22]. Drug susceptibility testing against rifampicin
(R), isoniazid (I), streptomycin (S), and ethambutol (E) was
performed by using the BACTEC 460-TB according to the
manufacturer’s instruction or standard proportion method on LJ
medium [21,23]. Multidrug-resistant (MDR) clinical isolates were
defined as simultaneous resistance to I+R, with or without
additional drug resistance.
Verbal consent for diagnosis of TB and detection of drug
resistance in M. tuberculosis isolates were obtained from all patients.
Nonetheless, since the resistant isolates were collected from
patients’ routine samples, this study was considered as a laboratory
study and ethics approval from institutional ethics committee was
not required.
DNA extraction
A loopful of bacteria colonies was suspended in 400 ml1 6TE
buffer (10 mM Tris, 1 mM EDTA, pH 8.0), and inactivated at
80uC for 20 minutes. Bacterial DNA was extracted by the
standard cetyl-trimethyl ammonium bromide (CTAB) (Merck,
Darmstadt, Germany) method, as described previously [24]. The
pellet of DNA was dried at room temperature, resuspended in 16
TE buffer and stored at 4uC until use.
Spoligotyping
Spoligotyping was carried out with a commercial kit (Isogen
Bioscience BV, Maarssen, The Netherlands) according to the
manufacturer’s instructions [11]. The 43 spacers between the
direct repeats in the target region were amplified by using DRa
biotinylated at the 59 end and DRb primers. The PCR product
was hybridized to a membrane containing 43 oligonucleotides
derived from the spacer sequences of M. tuberculosis H37Rv and
M.bovis BCG P3 by reverse line blotting. M. tuberculosis H37Rv and
M.bovis BCG P3 were used as control for spoligotyping.
Spoligotypes results were converted into octal code and in the
SITVIT2 proprietary database of the Pasteur Institute of
Guadeloupe, which is an updated version of the previously
released SpolDB4 database (available at http://www.pasteur-
guadeloupe.fr:8081/SITVITDemo). At the time of the present
study, the database contained genotyping information on about
67,000 M. tuberculosis clinical isolates from 160 countries of origin.
In this database, spoligotype international type (SIT) designates a
spoligotyping pattern shared by two or more patient isolates.
Major spoligotyping-based phylogenetic clades were assigned
according to signatures provided in SpolDB4.
IS6110-RFLP typing
IS6110-RFLP genotyping was performed by the standardized
methods described previously [25]. Briefly, the extracted DNA of
clinical isolates was digested with PvuII enzyme and DNA
fragments were subjected to electrophoresis. The restriction
fragments on the gel were denatured, blotted onto nylon
membrane by the alkaline transfer procedure and hybridized by
IS6110 probe. After hybridization, the results were analyzed by
using H37Rv as an internal marker, and comparison was done
using Bionumerics (Applied Maths, Sint-Martens-Latem, Bel-
gium).
Results
Drug susceptibility
All of the M. tuberculosis isolates were resistant to at least one of
the major antituberculous drugs. Seventy-three of the 95 M.
tuberculosis isolates (76.8%) were resistant to isoniazid, 45 (47.4%)
Table 1. Drug resistance patterns of the 95 drug-resistant M.
tuberculosis isolates from Ankara, Turkey.
Drugs
Number of the resistant isolates
n( % )
Streptomycin (S) 32(33.6)
Isoniazid (I) 73 (76.8)
Rifampicin (R) 45 (47.4)
Ethambutol (E) 31 (32.6)
S+I 12 (12.6)
I+E 2 (2.1)
R+E 2 (2.1)
S+I+R 5 (5.3)
I+R+E 14 (14.7)
S+I+R+E 10 (10.5)
Total MDR (I+R) 40 (42.1)
Total 95
doi:10.1371/journal.pone.0030331.t001
Drug-Resistant TB in Ankara, Turkey
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30331Figure 1. Tree of spoligotype M. tuberculosis isolates (n=95 strains), by using the PAUP 4.0b software and the UPGMA method.
aSIT,
Spoligotype International Type as defined in the SITVIT2 proprietary database of the Pasteur Institute of Guadeloupe. In the figure, the column below
the subtitle SIT shows the individual SIT number followed by strain number.
doi:10.1371/journal.pone.0030331.g001
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streptomycin and 31 (32.6%) were resistant to e ´thambutol, and
the proportion of MDR isolates was 42.1% (Table 1).
Spoligotyping
Spoligotyping of the 95 M. tuberculosis isolates yielded 35
different patterns, 20 of these patterns were unique (1 isolate
only), whereas 15 patterns containing 75 isolates were clustered (2
to 16 isolates per cluster, clustering rate of 79%, note that the
detailed spoligotyping results are summarized in Table 2, and the
UPGMA tree illustrated in Figure 1). Ninety of the 95 M.
tuberculosis isolates belonged to 30 shared types (SITs), 4 of these
SITs containing 8 isolates were newly created in the database,
whereas 26 SITs containing 82 isolates matched preexisting
patterns. Regarding 4 newly-created SITs, 2 included isolates
unique to this study, 1 matched with an orphan from Italy, and
another an orphan from the United States. Regarding the
distribution of shared types, SIT41 (Turkey family) predominated
in our setting with 19/95 (20%) of the isolates, and was followed
by SIT53 (ill-defined T) with 15/95 or 15.8% of isolates, SIT47
and SIT50 with 6/95 (6.3%) of the isolates, SIT1 and SIT4 with
5/95 (5.3%) of the isolates, and other less frequent SITs
representing 1–3 isolates (Table 2).
Thus the major lineages observed ranked in the following order:
Haarlem, 23/95 or 24.2%; ill-defined T superfamily (not a lineage
sensu stricto since it is defined by default), 22/95 or 23.2%; the
Turkey family (19/95, 20%; previously designated as LAM7-
TUR), Beijing, 6/95 or 6.3%; LAM (Latin-America & Mediter-
ranean), 5/95 or 5.3%; Manu, 3/95 or 3.2%; S, 1/95 or 1%.
Comparison of the spoligotyping results with the updated
SITVIT2 database revealed that 5 patterns did not match any
existing isolate, and these were designated as orphans (Table 3). Of
the 40 MDR isolates, 18 (45%) corresponded to unique patterns
within this study as opposed to 22 (55%) clustered isolates (6
clusters containing 2 to 8 isolates per cluster). The distribution of
lineages among MDR isolates was as follows: ill-defined T
superfamily (12/40, 30%), Haarlem (8/40, 20%), the Turkey
family (which was previously labeled as LAM7-TUR; 5/40,
12.5%), Beijing (4/40, 10%), LAM (3/40, 7.5%), and Manu (1/
40, 2.5%), lineages.
IS6110-RFLP typing
IS6110-RFLP typing of 87 isolates (because of culture contam-
ination, 8 isolates were not typed by IS6110-RFLP) identified 76
fingerprint patterns, 7 were clustered including 18 isolates with a
clustering rate of 20.7%, the remaining 69 were unique. The
number of IS6110 copies varied from 2 to 14; 29.9% of the isolates
were low-copy-number isolates having less than six copies of
IS6110. A combination of IS6110-RFLP and spoligotyping reduced
the number of clustered isolates to 10 and the clustering rate to
11.5%.
Discussion
Antituberculous drug resistance, especially MDR is a major
factor threatening the success of TB control programs [26]. In this
context, the molecular typing of M. tuberculosis clinical isolates
provides with useful data about success of TB control and
treatment protocols in a given population [16,27]. By calculating
the rate of clustering, efficacy of TB control program in a study
population can be estimated [16]. Indeed, it is generally accepted
that clustering indicates ongoing or recent transmission, while
unique patterns indicate reactivation events [16,28]. In this study,
spoligotyping of the 95 drug-resistant M. tuberculosis clinical isolates
resulted in a very high clustering rate (79%). This clustering rate
was similar to the results of the previous studies used spoligotyping
(77%, 76%, 85%) in Turkey [8,13,14]. These rates are closer to
the rates reported in Harare, Zimbabwe (84.1%) and in Finland
(90%), but much higher than the rates of clustered drug-resistance
cases observed in studies performed in Sweden (23.6%) and India
(43.5%) [9,17,18,29]. Analysis of the resistance patterns revealed
that 42% of patients in our setting were infected with MDR
isolates, divided in 6 different clusters belonging to LAM, the
Turkey family, Beijing, H1, H3 and T (a clustering rate of 55%).
These results seem to argue in favor of inadequate monitoring and
control of drug resistant TB in Ankara. Nonetheless, since
spoligotyping used alone may overestimate the proportion of
clustered M. tuberculosis isolates as compared to IS6110-RFLP and/
or MIRU-VNTR, we further evaluated these typing results by
spoligotyping and IS6110-RFLP used in combination, which
reduced the clustering rate dramatically from 79% to 11.5% in our
study population.
Major spoligotyping-based lineages of M. tuberculosis clinical
isolates from different geographical areas of Turkey were assessed
in previous studies [8,14,16]. Two of these studies showed that
LAM7-TUR lineage corresponded to the most frequent spoligo-
type pattern SIT41 (21% and 22.5%, respectively) in the
respective study populations [8,16]; which allowed the description
of a new phylogeographically-specific clone of M. tuberculosis,
designated LAM7-TUR [16]. In another study from Ankara
performed on 114 isolates, the frequency of this spoligotype was
7.9% and it was the 2
nd most prevalent spoligotype pattern [14]. A
retrospective analysis of a paper on 374 isolates from Turkey
published in 2005, i.e., a year before the designation LAM7-TUR
was officially published, showed that as high as 14.4% of M.
tuberculosis isolates belonged to LAM7-TUR which stood as the 2
nd
most common spoligotype [13]. However, since the description of
this M. tuberculosis clone with high phylogenetical specificity for
Turkey, a recent paper showed that although LAM7-TUR isolates
Table 3. Description of the orphan isolates (n=5) after comparison of the spoligotype patterns of the drug-resistant M.
tuberculosis isolates from Ankara with the SITVIT2 database.
Iso Number Spoligotype Description Octal Number Lineage
TUR062005300G11 %&&&&&&&&%&&&&&&&&&&&&&&&&&&&&%&%%&&&&&&&&& 377377777723771 Manu
TUR082005200H25 &&&&&%%%%%%%%%%%%%%%%%%%%%%%&&&%%%%%%&&&&&& 760000000340371 Unknown
TUR082004200H40 &&&&&&%&&&&&&&&&&&&%%%%%&%%&&&&&%%%%&&&&&&& 773777404760771 Turkey
TUR082004200H42 &&&&&&%&&&&&&&&&&&&&&&&&&&%&&&&&%%%%&&&&&&& 773777776760771 Unknown
TUR092005300R56 &&&&&&&%%&&&&&&&&&&&&&&&&&&&%%%&%%%%&&&%%%% 774777777420700 Haarlem
doi:10.1371/journal.pone.0030331.t003
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belong to the LAM lineage sensu-stricto [30]; instead these strains
share a SNP ligC (809 tgg [trp] to ttg [leu]) with the T3-Osaka
lineage [30]. Nonetheless, these new results do not question the
phylogeographical specificity of this lineage defined by its
prototype SIT41 in the SpolDB4 database [27]. Awaiting a
detailed molecular characterization of this unique lineage in future
studies, we have hereby renamed the LAM7-TUR lineage as the
‘‘Turkey’’ family.
The current study also showed that 19/95 or 20% of the drug-
resistant isolates belonged to the Turkey family, and represented
5/40 or 12.5% of the MDR isolates. The proportion of drug-
resistant versus MDR isolates for other major lineages was:
Haarlem (24.2% vs. 20%), ill-defined T superfamily (23.2% vs.
30%), Beijing (6.3% vs. 10%), Manu (3.2% vs. 2.5%) and S (1%
vs. 0%) lineages. However, if the percentage of MDR isolates was
considered within each of the families individually, the order was
as follows: Beijing (4/6, 66.7%), LAM (3/5, 60%), T (12/22,
54.5%), Haarlem (8/23, 34.8%), Manu (1/3, 33.3%), the Turkey
family (5/19, 26.3%), and S (0/1, 0%).
According to the previous studies performed in Turkey, the four
most prevalent spoligotype patterns in Turkey were: ill-defined T/
SIT53, Turkey family/SIT41, H1/SIT47, and H3/SIT50
[8,13,14,16]. Although, additional analysis of isolates from various
regions of Turkey will be necessary to determine the actual
prevalence of these genotypes, our study corroborates these
findings and indicates that the Turkey family can be considered
as a major type with demonstrated phylogeographical specificity
for Turkey as opposed to SIT47, SIT50 and SIT53 that are
distributed equally in Turkey and elsewhere [10,20,30,31].
Indeed, a cross-checking of the SITVIT2 database on November
24
th 2011 showed that Turkey/SIT41 isolates in the database
(n=357) are almost exclusively isolated in Turkey (n=212 or
59.38% of the isolates). The results of this study also revealed 4
newly-created shared types (SIT2900, SIT2901, SIT2902 and
SIT2903) and 2 of these containing 5 strains were exclusively
found in the present study (SIT2902, SIT2903; Table 2). Coupled
to the observation of 5 orphan clinical isolates (Table 3), our study
indicates that the bulk of TB in Ankara is caused both by strains
that are restricted to our local population (as reflected by newly-
created shared types or orphans restricted to Ankara as well as
endemic strains such as SIT41 belonging to the Turkey family)
and those that are present elsewhere (SIT47, SIT50 and SIT53)
[8,14,16].
Beijing genotype of M. tuberculosis has been observed to be highly
prevalent throughout Asia and in the countries of the former
Soviet Union [32]. Although the Beijing genotype was found only
in 6/95 or 6.3% isolates in our study, it corresponded to the
lineage with the highest proportion of MDR isolates since 4/6
isolates or 66.7% were MDR. As summarized in Table 4, the
relative occurrence of Beijing genotype at 6.3% in the present
study was significantly higher than in previous studies from Turkey
(0.5%, 1.7%, and 1.8%, respectively) [8,13,14]. Seeing the sample
size, our attempts to compare lineages in case of MDR versus
monoresistant isolates did not result in any statistically significant
differences. For the same reason, one may be cautious not to
overestimate the prevalence of the Beijing genotype and its
probable role in current MDRTB transmission; nonetheless, these
observations should not be overlooked while considering the
emergence and spread of drug resistant and MDR-TB by the
national TB control program.
In conclusion, this study showed that the 5 major lineages
observed among the drug-resistant M. tuberculosis clinical isolates in
Ankara were: Haarlem 24.2%; ill-defined T superfamily 23.2%;
the Turkey family (previously designated as LAM7-TUR) 20%;
Beijing 6.3%; and LAM 5.3. A high proportion of these strains
(42.1%) corresponded to MDR isolates with the following main
lineages: T 30%; Haarlem 20%; the Turkey family 12.5%; Beijing
10%; and LAM 7.5. However, the order was inversed if the
percentage of MDR isolates was calculated within a genotypic
lineage individually as: Beijing 66.7%; LAM 60%; T 54.5%;
Haarlem 34.8%; Manu 33.3%; and the Turkey family 26.3%. We
showed that the bulk of drug-resistant TB in Ankara is caused both
by strains that are endemic to the local population (as reflected by
newly-created shared types or orphans restricted to Ankara as well
as endemic strains such as SIT41 belonging to the Turkey family)
and those that are present elsewhere in the world (SIT47, SIT50
and SIT53). Last but not least, the role of Beijing genotype in
current MDR-TB transmission in Ankara and elsewhere in
Turkey must be reassessed in future studies.
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